We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Just be clear, it’s not helping asthma or COPD per se , rather fighting a viral infection in those people that suffer with the afore mentioned. It could be useful against any viral infection in theory.
Our wholly-owned drug, SNG001, has already been well tolerated in clinical trials in more than 200 respiratory patients to date and has accelerated lung function recovery in two Phase II asthma trials in patients with a cold or flu infection.
Fingers crossed for all in need
The SNG clinical trial is privately funded, using £9m out of the £14m raised a couple of weeks ago. The trials mentioned yesterday as part of the UK Government Recovery Scheme are larger scale trials which are funded with Government/NHS/Public money. The advantages SNG have are: 1) First mover advantage i.e already started 2) Fully funded with shareholders money 3) Smaller scale with 100 patients needed (50 with SNG product, 50 with placebo)
The effect of the treatment is measured over a 2 week period but the ramp up period to have all 100 patients on board means that it will take up to 2 months to collect all the data & carry out the analysis. The upside for SNG shares is if “early” readings from the treatment are very positive, the company would issue an RNS re expanding the trial/collaboration with partners/fast track approval etc.
I think they had dosed 6 by Thursday at Southampton. I think they may have only started 4 days previous.
Roger, SNG a treatment yes, but to enable recovery and therefore a cure.
Would be good to know how many people are now part of SNG trial. Good rns last week informing of the first patient.
Hi Green,
No I don't think so,but i will let tge experts on here say fot definite. it looks like a race is on here to find something that might cure Covid-19. No mention of SNG which is a shame, but SNG is not a cure just a treatment
is this SNG technology???
The trial is being coordinated by researchers at the University of Oxford, led by Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, and Martin Landray, Professor of Medicine and Epidemiology at the Nuffield Department of Population Health.
To ensure that the healthcare system research resource is directed to benefit the national effort, the National Institute for Health Research (NIHR) has put in place a national process to prioritise COVID-19 research. The RECOVERY trial is one of those prioritised.
The study has received £2.1 million from UK Research and Innovation (UKRI) and the Department of Health and Social Care, through the NIHR. It is part of a wider £20 million rapid research response investment by the government to support looking at ways to tackle the coronavirus outbreak.
The move further bolsters the ‘research’ phase in the government’s science-led coronavirus action plan.
It follows decisive action by the UK’s medicines regulator to fast-track clinical trials for potential coronavirus treatments, meaning NHS patients could have faster access if medicines are proven to be effective.
The Medicines and Healthcare products Regulatory Agency (MHRA) has been working hard to put in place procedures to support manufacturers and researchers developing these treatments and approve clinical trial applications in days, rather than weeks. Its experience as a world-renowned regulator means these rapid approvals are based on the latest scientific advice and do not compromise the government’s top priority of maintaining patient safety.
Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, said:
The RECOVERY trial will provide much-needed evidence on the best care for patients with COVID-19. The more patients that are enrolled, the sooner we will know how best to treat this disease.
We are very grateful to those patients who are participating and to the hospital and research staff who are helping us to find the best treatments.
Notes to editor
See full details on the trial
Patients with COVID-19 are being offered the opportunity to participate in this trial. If they agree, they will be randomly allocated to standard of care alone, or standard of care plus 1 of 3 additional treatments
The trial began on 19 March. It was set up in record time: first protocol to first patient in 9 days and 13 days to reach 500 patients. Within the first 2 weeks, nearly 1,000 patients have been enrolled
The data will be analysed on a rolling basis so that any beneficial treatments can be identified as soon as possible. The faster that patients are recruited, the sooner the reliable results
The other 2 key national trials are PRINCIPLE and REMAP-CAP
Find out more about the NIHR’s national process to prioritise COVID-19 research. See details on the process and the new single point of entry for prio